
IMRX, also at ASCO - 17 month survival. Compare?
After Gemini hallucinated, I dug deeper and found that $IMRX reported 17 month median overall survival for metastatic pancreatic cancer. Looks like this is your typical systemic cancer treatment and there were predictably more AEs. Still, the market has responded favorably - up 4% today and even more postmarket.
Does this challenge the DRTS-growth narrative? I’m ignorant but seems relevant. Of course a local treatment like Alpha DART seems safer. Curious about folks’ opinions. https://www.stocktitan.net/news/IMRX/immuneering-reports-17-3-months-median-overall-survival-in-first-i7j9nn3xn2lj.html